EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Ahmad Masri, Mark V Sherrid, Theodore P Abraham, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M Kramer, Roberto Barriales-Villa, Anjali T Owens, Florian Rader, Sherif F Nagueh, Iacopo Olivotto, Sara Saberi und 15 weitere

Journal of Cardiac Failure · 2024-11 · 30 (11) · 1439-1448

DOI: 10.1016/j.cardfail.2024.02.020 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Cardiac Failure, 2024-11. Verfasst von Ahmad Masri und 26 weiteren Autor:innen. Beteiligte Einrichtung: Hypertrophic Cardiomyopathy Center, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, USA. Electronic address: mas…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cytokinetics Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). METHODS: Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤ 30 mmHg, left ventricular ejection fraction [LVEF] ≥ 60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] > 300 pg/mL) received aficamten 5-15 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks. RESULTS: We enrolled 41 patients (mean ± SD age 56 ± 16 years; 59% female). At Week 10, 22 (55%) patients experienced an improvement of ≥ 1 New York Heart Association class; 11 (29%) became asymptomatic. Clinically relevant improvements in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores occurred in 22 (55%) patients. Symptom relief was paralleled by reductions in NT-proBNP levels (56%; P < 0.001) and high-sensitivity cardiac troponin I (22%; P < 0.005). Modest reductions in LVEF (mean ± SD) of -5.4% ± 10 to 64.6% ± 9.1 were observed. Three (8%) patients had asymptomatic reduction in LVEF < 50% (range: 41%-48%), all returning to normal after 2 weeks of washout. One patient with prior history of aborted sudden cardiac death experienced a fatal arrhythmia during the study. CONCLUSIONS: Aficamten administration for symptomatic nHCM was generally safe and was associated with improvements in heart failure symptoms and cardiac biomarkers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04219826.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHumansFemaleMaleMiddle AgedAgedTreatment OutcomeNatriuretic Peptide, BrainCohort StudiesAdultPeptide FragmentsStroke VolumeEchocardiographyVentricular Function, LeftDose-Response Relationship, Drug

Stichwörter der Autor:innen

Hypertrophic cardiomyopathyaficamtencardiac myosin inhibitornHCM

Substanzen

Natriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Peptide Fragments

Autor:innen und Institutionen

  • Hypertrophic Cardiomyopathy Center, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, USA. Electronic address: masria@ohsu.edu.
  • Hypertrophic Cardiomyopathy Program, Leon H. Charney Division of Cardiology, NYU Langone Health, New York, NY, USA.
  • University of California San Francisco, San Francisco, CA, USA.
  • Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Hospital Universitario Puerta de Hierro de Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
  • Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA.

Förderung

  • Cytokinetics Inc

Zitieren

APA

Masri, A., Sherrid, M. V., Abraham, T. P., Choudhury, L., Garcia-Pavia, P., Kramer, C. M., Barriales-Villa, R., Owens, A. T., Rader, F., Nagueh, S. F., Olivotto, I., Saberi, S., Tower-Rader, A., Wong, T. C., Coats, C. J., Watkins, H., Fifer, M. A., Solomon, S. D., Heitner, S. B., …, & REDWOOD-HCM Investigators (2024). Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. Journal of Cardiac Failure, 30(11), 1439-1448. https://doi.org/10.1016/j.cardfail.2024.02.020

Vancouver

Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, et al. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. Journal of Cardiac Failure. 2024;30(11):1439-1448. doi:10.1016/j.cardfail.2024.02.020

BibTeX
@article{Masri2024,
  author = {Masri, Ahmad and Sherrid, Mark V and Abraham, Theodore P and Choudhury, Lubna and Garcia-Pavia, Pablo and Kramer, Christopher M and Barriales-Villa, Roberto and Owens, Anjali T and Rader, Florian and Nagueh, Sherif F and Olivotto, Iacopo and Saberi, Sara and Tower-Rader, Albree and Wong, Timothy C and Coats, Caroline J and Watkins, Hugh and Fifer, Michael A and Solomon, Scott D and Heitner, Stephen B and Jacoby, Daniel L and Kupfer, Stuart and Malik, Fady I and Meng, Lisa and Sohn, Regina L and Wohltman, Amy and Maron, Martin S and REDWOOD-HCM Investigators, REDWOOD-HCM Investigators},
  title = {Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4},
  journal = {Journal of Cardiac Failure},
  year = {2024},
  volume = {30},
  number = {11},
  pages = {1439--1448},
  doi = {10.1016/j.cardfail.2024.02.020}
}
Kostenlos starten →